Mostrar el registro sencillo del ítem

dc.contributor.authorPearson, Mark S
dc.contributor.authorTedla, Bemnet A
dc.contributor.authorMekonnen, Gebeyaw G
dc.contributor.authorProietti, Carla
dc.contributor.authorBecker, Luke
dc.contributor.authorNakajima, Rie
dc.contributor.authorJasinskas, Al
dc.contributor.authorDoolan, Denise L
dc.contributor.authorAmoah, Abena S
dc.contributor.authorKnopp, Stefanie
dc.contributor.authorRollinson, David
dc.contributor.authorAli, Said M
dc.contributor.authorKabole, Fatma
dc.contributor.authorHokke, Cornelis H
dc.contributor.authorAdegnika, Akim A
dc.contributor.authorField, Matt A
dc.contributor.authorvan Dam, Govert
dc.contributor.authorCorstjens, Paul L A M
dc.contributor.authorMduluza, Takafira
dc.contributor.authorMutapi, Francisca
dc.contributor.authorOeuvray, Claude
dc.contributor.authorGreco, Beatrice
dc.contributor.authorChaiyadet, Sujittra
dc.contributor.authorLaha, Thewarach
dc.contributor.authorCai, Pengfei
dc.contributor.authorMcManus, Donald P
dc.contributor.authorBottazzi, Maria Elena
dc.contributor.authorFelgner, Philip L
dc.contributor.authorSotillo, Javier 
dc.contributor.authorLoukas, Alex
dc.date.accessioned2022-05-11T13:11:26Z
dc.date.available2022-05-11T13:11:26Z
dc.date.issued2021-11
dc.identifier.citationLancet Microbe. 2021 Nov;2(11):e617-e626.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14393
dc.description.abstractBackground: Sensitive diagnostics are needed for effective management and surveillance of schistosomiasis so that current transmission interruption goals set by WHO can be achieved. We aimed to screen the Schistosoma haematobium secretome to find antibody biomarkers of schistosome infection, validate their diagnostic performance in samples from endemic populations, and evaluate their utility as point of care immunochromatographic tests (POC-ICTs) to diagnose urogenital schistosomiasis in the field. Methods: We did a biomarker identification study, in which we constructed a proteome array containing 992 validated and predicted proteins from S haematobium and screened it with serum and urine antibodies from endemic populations in Gabon, Tanzania, and Zimbabwe. Arrayed antigens that were IgG-reactive and a select group of antigens from the worm extracellular vesicle proteome, predicted to be diagnostically informative, were then evaluated by ELISA using the same samples used to probe arrays, and samples from individuals residing in a low-endemicity setting (ie, Pemba and Unguja islands, Zanzibar, Tanzania). The two most sensitive and specific antigens were incorporated into POC-ICTs to assess their ability to diagnose S haematobium infection from serum in a field-deployable format. Findings: From array probing, in individuals who were infected, 208 antigens were the targets of significantly elevated IgG responses in serum and 45 antigens were the targets of significantly elevated IgG responses in urine. Of the five proteins that were validated by ELISA, Sh-TSP-2 (area under the curve [AUC]serum=0·98 [95% CI 0·95-1·00]; AUCurine=0·96 [0·93-0·99]), and MS3_01370 (AUCserum=0·93 [0·89-0·97]; AUCurine=0·81 [0·72-0·89]) displayed the highest overall diagnostic performance in each biofluid and exceeded that of S haematobium-soluble egg antigen in urine (AUC=0·79 [0·69-0·90]). When incorporated into separate POC-ICTs, Sh-TSP-2 showed absolute specificity and a sensitivity of 75% and MS3_01370 showed absolute specificity and a sensitivity of 89%. Interpretation: We identified numerous biomarkers of urogenital schistosomiasis that could form the basis of novel antibody diagnostics for this disease. Two of these antigens, Sh-TSP-2 and MS3_01370, could be used as sensitive, specific, and field-deployable diagnostics to support schistosomiasis control and elimination initiatives, with particular focus on post-elimination surveillance.es_ES
dc.description.sponsorshipThis study received financial support from Merck Global Health Institute and the Australian Trade and Investment Commission (Australian Tropical Medicine Commercialisation grants programme ATMC50322). Research for the Zanzibar Elimination of Schistosomiasis Transmission project was funded by the University of Georgia Research Foundation, which is funded by the Bill & Melinda Gates Foundation for the Schistosomiasis Consortium for Operational Research and Evaluation projects (prime award number 50816, sub-award number RR374-053/4893206). SK received financial support by sub-award number RR374-053/4893196 and via direct grants from the Gates Foundation (investment identification numbers OPP1191423 and OPP1198086). AL was funded by a National Health and Medical Research Council Senior Principal Research Fellowship (number APP1117504). BAT was funded by a James Cook University Postgraduate Scholarship. GGM was funded by an Australian Institute of Tropical Health and Medicine postgraduate scholarship. Funding was granted to AAA by a European and Developing Countries Clinical Trials Partnership senior fellowship training award (number TA_11_40200). FM was funded by the Thrasher Research Fund (number 12440) and the Wellcome Trust (number 108061/Z/15/Z).es_ES
dc.language.isoenges_ES
dc.publisherElsevier es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleImmunomics-guided discovery of serum and urine antibodies for diagnosing urogenital schistosomiasis: a biomarker identification studyes_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID34977830es_ES
dc.format.volume2es_ES
dc.format.number11es_ES
dc.format.pagee617-e626es_ES
dc.identifier.doi10.1016/S2666-5247(21)00150-6es_ES
dc.contributor.funderAustralian Trade and Investment Commission es_ES
dc.contributor.funderFundación Merck Salud es_ES
dc.contributor.funderBill & Melinda Gates Foundation es_ES
dc.contributor.funderAustralian Institute of Tropical Health and Medicine es_ES
dc.contributor.funderUniversity of Georgia (Estados Unidos)es_ES
dc.contributor.funderNational Health and Medical Research Council (Australia) es_ES
dc.contributor.funderJames Cook University (Australia) es_ES
dc.contributor.funderWellcome Trust es_ES
dc.contributor.funderThrasher Research Fund es_ES
dc.contributor.funderEuropean and Developing Countries Clinical Trialses_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2666-5247es_ES
dc.identifier.journalThe Lancet. Microbees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional